Bronchogen Airway Hyperresponsiveness Price

Direct Answer: Sourcing Costs and Quality Benchmarks for Bronchogen

Research-grade Bronchogen pricing typically ranges between $40 and $90 per 10 mg vial, depending on analytical verification standards, batch scale, and purity level. When investigating airway hyperresponsiveness in preclinical settings, institutional laboratories prioritize documented lot-specific HPLC purity (≥98%) and low endotoxin levels over initial purchase price to guarantee experimental reproducibility.

Selecting a supplier based solely on low unit cost often introduces risks such as unverified peptide content, residual trifluoroacetic acid (TFA) contamination, or batch-to-batch inconsistency. High-tier suppliers like PX1 Research provide full batch transparency, ISO 17025 accredited laboratory testing, and certified chains of custody, ensuring that your expenditure directly translates to dependable laboratory data.

Molecular Structure and Mechanism of Bronchogen (Ala-Glu-Asp-Leu)

Bronchogen is a synthetic short tetrapeptide consisting of the amino acid sequence L-alanyl-L-glutamyl-L-aspartyl-L-leucine (Ala-Glu-Asp-Leu). Belonging to the class of short peptide bioregulators originally developed by Khavinson and colleagues, Bronchogen was engineered to mimic natural chromatin-interacting peptides found in respiratory tract tissues.

At the cellular level, short peptides like Bronchogen are hypothesized to interact directly with the major and minor grooves of DNA, specifically binding to histone proteins or promoter regions of specific genes. In vitro assays demonstrate that Ala-Glu-Asp-Leu can penetrate cellular and nuclear membranes without requiring specialized transporter systems, altering gene expression patterns associated with structural proteins and inflammatory cascades within bronchial epithelial cells.

Understanding this molecular foundation is essential when designing in vitro models. Researchers interested in broader genomic interaction mechanisms often cross-reference data from our peptide research hub, which details structural kinetics across various short-chain synthetic bioregulators.

Preclinical Findings on Airway Hyperresponsiveness and Bronchial Repair

Airway hyperresponsiveness (AHR) is a hallmark of inflammatory respiratory pathology, characterized by exaggerated bronchoconstriction in response to exogenous or endogenous stimuli. In rodent models of acute and chronic pulmonary inflammation, researchers examine how peptide intervention influences bronchial wall remodeling, smooth muscle hyperplasia, and goblet cell metaplasia.

Preclinical studies suggest that administration of Bronchogen in animal models of induced airway hypersensitivity leads to a reduction in hyperresponsiveness parameters. Specifically, isolated tissue assays indicate decreases in contractile responses to methacholine or histamine challenges following peptide exposure. Histological evaluations of lung tissue in these models show attenuated inflammatory cell infiltration—particularly eosinophils and neutrophils—into the bronchoalveolar lavage fluid (BALF).

Furthermore, in vitro data indicate that Bronchogen modulates cytokine release, downregulating pro-inflammatory signal transducers such as IL-4, IL-5, and TNF-alpha, while promoting expression of structural proteins like surfactant protein A (SP-A). Laboratories studying these pathways frequently acquire validated research-grade Bronchogen to benchmark tissue-specific transcriptional shifts.

Evaluating Sourcing Costs vs. Analytical Rigor in Research Procurement

When analyzing the bronchogen airway hyperresponsiveness price across vendors, researchers must look beyond the sticker price to evaluate the total value of analytical validation. Low-cost peptides that lack comprehensive quality testing often cost laboratories far more in failed assays, non-reproducible baseline data, and compromised cell cultures.

A rigorous cost analysis must factor in supplier manufacturing credentials. Essential quality verification criteria include:

1. Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) establishing ≥98% chemical purity. 2. Electrospray Ionization Mass Spectrometry (ESI-MS) confirming exact molecular weight (446.45 g/mol). 3. Endotoxin testing via Limulus Amebocyte Lysate (LAL) assay to ensure levels below 0.01 EU/mg, preventing unspecific immune stimulation in sensitive pulmonary cultures. 4. Domestic US manufacturing in GMP-compliant facilities to guarantee lot-to-lot consistency.

For institutions managing larger projects or ongoing preclinical screening pipelines, securing standardized materials via bulk institutional accounts provides both volume cost optimization and guaranteed single-lot batch consistency.

Comparative Peptide Analysis in Respiratory and Bioregulatory Research

To contextualize Bronchogen's activity in preclinical literature, researchers frequently compare its organ-specific profile with other peptide regulators. While Bronchogen exhibits high specificity for bronchial tissue and pulmonary gene transcription, other short-chain and signal peptides operate across overlapping repair or bioregulatory pathways.

For example, Epitalon research focuses primarily on telomerase activation and neuroendocrine modulation, whereas Thymogen mechanisms center on T-cell differentiation and general systemic immune response. Similarly, investigators evaluating tissue protection and cellular migration often compare pulmonary bioregulators against BPC-157 cytoprotection models or examine generalized extracellular matrix modulation using Vilon bioregulatory pathways.

Understanding these distinct tissue affinities allows research teams to select the appropriate compound or combination strategy for their specific experimental endpoints. Explore our complete catalog of research peptides to review molecular weights, analytical specifications, and purity ratings across these related compound classes.

Handling, Storage, and Reconstitution Protocol for Laboratory Use

To maintain the chemical stability of synthetic Bronchogen and avoid premature hydrolysis or peptide aggregation, strict laboratory handling protocols must be observed. Upon receipt, lyophilized peptide powder should be stored at -20°C in a dry environment, protected from light exposure.

Reconstitution should be performed under sterile laminar flow conditions using bacteriostatic water, sterile normal saline (0.9% NaCl), or cell-culture grade phosphate-buffered saline (PBS), depending on the requirements of your assay system. Avoid vigorous vortexing; instead, gently swirl or invert the vial to achieve complete solution.

Once reconstituted, aliquots should be prepared to minimize freeze-thaw cycles. Reconstituted solutions maintained at 4°C are generally stable for short-term handling (up to 7-14 days), whereas long-term storage of aliquots requires -80°C. Following these standard operating procedures protects the integrity of your sample and prevents batch degradation during extended airway hyperresponsiveness study protocols.

Quality Verification: Third-Party COAs and Batch Traceability

PX1 Research maintains an unwavering commitment to analytical purity and transparency. Every lot of synthetic peptide synthesized for our inventory undergoes comprehensive testing by independent, ISO 17025 accredited analytical laboratories.

Our Certificates of Analysis (COAs) provide complete spectrum data, including RP-HPLC chromatograms showing exact retention times and peak area integration, along with mass spectrometry reports matching theoretical molecular mass. We also supply explicit endotoxin quantification data, confirming that our peptides meet the stringent demands of cell culture and animal microinjection protocols.

By enforcing these high standards, PX1 Research eliminates the ambiguity surrounding raw material quality, allowing principal investigators to focus on advancing scientific discovery without questioning compound identity or concentration accuracy.